<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548769" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548769/" /><meta name="ncbi_pagename" content="Pirfenidone - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Pirfenidone - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Pirfenidone" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/06/24" /><meta name="citation_pmid" content="31644078" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548769/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Pirfenidone" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/06/24" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548769/" /><meta name="description" content="Pirfenidone is an orally available pyridinone derivative that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during pirfenidone therapy are not uncommon, but it has yet to be implicated in cases of clinically apparent liver injury with jaundice." /><meta name="og:title" content="Pirfenidone" /><meta name="og:type" content="book" /><meta name="og:description" content="Pirfenidone is an orally available pyridinone derivative that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during pirfenidone therapy are not uncommon, but it has yet to be implicated in cases of clinically apparent liver injury with jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548769/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Pirfenidone/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548769/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AEAB4046729C100000000061701D9.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548769_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548769_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/PiperacillinTazob/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Piroxicam/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548769_"><span class="title" itemprop="name">Pirfenidone</span></h1><p class="small">Last Update: <span itemprop="dateModified">June 24, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Pirfenidone.OVERVIEW"><h2 id="_Pirfenidone_OVERVIEW_">OVERVIEW</h2><div id="Pirfenidone.Introduction"><h3>Introduction</h3><p>Pirfenidone is an orally available pyridinone derivative that inhibits collagen formation and is used to treat idiopathic pulmonary fibrosis. Elevations in serum enzyme levels during pirfenidone therapy are not uncommon, but it has yet to be implicated in cases of clinically apparent liver injury with jaundice.</p></div><div id="Pirfenidone.Background"><h3>Background</h3><p>Pirfenidone (pir fen' i done) is an orally available, antiinflammatory and antifibrotic agent that is used to treat idiopathic pulmonary fibrosis. It is a small molecular weight phenyl substituted pyridinone that has antifibrotic activity both in vitro and in vivo. In animal models, pirfenidone decreases fibroblast proliferation and reduces transforming growth factor-beta (TGF-&#x003b2;) synthesis and activation of fibrogenic pathways. In several prospective, placebo controlled trials, pirfenidone was found to reduce the progression of fibrosis and worsening of lung function in patients with idiopathic pulmonary fibrosis. Pirfenidone was approved for use in the United States in 2014, but has been available in other countries for much longer. It is available as capsules of 267 mg under the brand name Esbriet. The typical initial dose in adults is one capsule (267 mg) orally three times daily, which can be increased to 3 capsules three times daily based upon tolerance. Side effects are not uncommon, but are generally mild and can include photosensitivity, rash and gastrointestinal upset with nausea, diarrhea, dyspepsia, reflux and abdominal pain.</p></div><div id="Pirfenidone.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large randomized controlled trials, serum aminotransferase elevations more than 3 times the upper limit of normal (ULN) occurred in 4% of pirfenidone- compared to less than 1% of placebo-treated patients. The elevations were generally asymptomatic and short lived, resolving with or without dose modification and requiring drug discontinuation in approximately 1% of patients. Despite the frequency of serum enzyme elevations during therapy, clinically apparent liver injury was not reported in preregistration studies. Nevertheless, since the general availability of pirfenidone in the United States and during years of clinical use elsewhere, there have been isolated case reports of clinically apparent liver injury due to pirfenidone, some of which were severe and even fatal. The latency to onset ranged from one month to one year and the injury was usually hepatocellular or mixed. Immunoallergic features were not common.</p><p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p></div><div id="Pirfenidone.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which pirfenidone might cause liver injury is not known. It is metabolized in the liver largely via the cytochrome P450 system, predominantly CYP 1A2, and liver injury may be due to production of a toxic or immunogenic metabolite. Pirfenidone is also susceptible to drug-drug interactions with strong inducers or inhibitors of CYP 1A2 (such as fluvoxamine).</p></div><div id="Pirfenidone.Outcome_and_Management"><h3>Outcome and Management</h3><p>While chronic therapy with pirfenidone can be associated with mild-to-moderate serum aminotransferase elevations, it has only rarely been linked to cases of clinically apparent liver injury. Nevertheless, monitoring of serum aminotransferase levels monthly during the first 6 months and every 3 months thereafter is recommended. Patients who develop aminotransferase elevations on therapy should be monitored more carefully, and pirfenidone should be permanently discontinued if jaundice or symptoms of liver injury arise or if serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> or <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels rise above 5 times the ULN.</p><p>Drug Class: Pulmonary <a class="def" href="/books/n/livertox/glossary/def-item/glossary.fibrosis/">Fibrosis</a> Agents</p><p>Other Drugs in the Class: <a href="/books/n/livertox/Nintedanib/">Nintedanib</a></p></div></div><div id="Pirfenidone.CASE_REPORT"><h2 id="_Pirfenidone_CASE_REPORT_">CASE REPORT</h2><div id="Pirfenidone.Case_1_Fatal_acute_liver_inj"><h3>Case 1. Fatal, acute liver injury attributed to pirfenidone.(<a class="bk_pop" href="#Pirfenidone.REF.1">1</a>)</h3><p>An 77 year old man with Parkinson disease and idiopathic pulmonary fibrosis developed anorexia and nausea within 2 to 3 weeks of starting pirfenidone (200 mg three times daily), which was followed in the next 1 to 2 weeks by dark urine, jaundice and altered sensorium. He had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. He had been diagnosed with Parkinson disease 5 years previously and had been on a stable dose of levodopa/carbidopa for years. He denied taking other medications, over-the-counter drugs or herbal products and had no history of drug allergy. His liver test results had been normal in the past. On presentation, he was jaundiced, tachypneic, hypotensive and mildly encephalopathic. Laboratory testing showed total bilirubin of 12.8 mg/dL (direct 7.8), <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 526 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 1260 U/L, Alk P 434 U/L and LDH 687 U/L [R= 4.0]. The INR was 2.1 and serum ammonia 330 &#x000b5;mol/L. He had elevations in serum creatinine [2.1 mg/dL] and blood lactate [6.1 mmol/L] with severe acidosis [pH 7.04]. He was admitted to the intensive care unit and treated with N-acetyl cysteine. Tests for acute hepatitis A, B, C and E were negative as were markers for cytomegalovirus, Epstein Barr virus and herpes virus infection. Routine autoantibodies were undetectable and immunoglobulin levels were normal. Imaging of the liver showed no evidence of biliary obstruction. He rapidly developed multiorgan failure and died within 4 days of admission. Autopsy showed confluent and bridging necrosis, collapse and few surviving, swollen and vacuolated hepatocytes, no fibrosis and mild portal inflammation suggestive of acute liver failure due to drug induced liver injury.</p><div id="Pirfenidone.Key_Points"><h4>Key Points</h4><div id="Pirfenidone.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548769/table/Pirfenidone.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Pirfenidone.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Pirfenidone.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Pirfenidone.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pirfenidone (600 mg daily)</td></tr><tr><th id="hd_b_Pirfenidone.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Pirfenidone.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=9.6)</td></tr><tr><th id="hd_b_Pirfenidone.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Pirfenidone.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (jaundice, hospitalization, death)</td></tr><tr><th id="hd_b_Pirfenidone.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Pirfenidone.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3-4 weeks</td></tr><tr><th id="hd_b_Pirfenidone.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Pirfenidone.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_Pirfenidone.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Pirfenidone.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Levodopa/carbodopa for several years</td></tr></tbody></table></div></div></div><div id="Pirfenidone.Comment"><h4>Comment</h4><p>This was a dramatic example of acute liver failure arising in an elderly man who had recently started pirfenidone. The precipitous onset and course suggests that shock and hypoxia may have contributed to the severity of the injury and fatal outcome. While instances of serum aminotransferase elevations without jaundice have been reported with pirfenidone therapy, there have been no instances of moderate injury with jaundice and a self-limited course reported in the literature. Nevertheless, this case is somewhat convincing. No other cause of jaundice was found despite extensive testing and the autopsy was consistent with drug induced liver injury. The product label for pirfenidone states that cases of hepatitis, jaundice and fatal hepatotoxicity during pirfenidone therapy have been reported to the sponsor. Furthermore, it recommends regular monitoring of liver tests before and monthly for the first 6 months of treatment. In this case, the liver injury arose during the first month of treatment and would not have been prevented by such screening. Furthermore, the capsule size used was lower than the standard (200 mg rather than 267 mg amounts) and there was no dose escalation to 3 capsules 3 times daily as is recommended in treatment of patients with idiopathic pulmonary fibrosis.</p></div></div></div><div id="Pirfenidone.PRODUCT_INFORMATION"><h2 id="_Pirfenidone_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Pirfenidone &#x02013; Esbriet&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Pulmonary <a class="def" href="/books/n/livertox/glossary/def-item/glossary.fibrosis/">Fibrosis</a> Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Pirfenidone" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Pirfenidone.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Pirfenidone_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Pirfenidone.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548769/table/Pirfenidone.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Pirfenidone.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Pirfenidone.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Pirfenidone.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Pirfenidone.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Pirfenidone.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Pirfenidone.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pirfenidone</td><td headers="hd_h_Pirfenidone.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135003538" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">53179-13-8</a></td><td headers="hd_h_Pirfenidone.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C12-H11-N-O</td><td headers="hd_h_Pirfenidone.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135003538" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135003538" alt="image 135003538 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Pirfenidone.CITED_REFERENCE"><h2 id="_Pirfenidone_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Pirfenidone.REF.1">Verma N, Kumar P, Mitra S, Taneja S, Dhooria S, Das A, Duseja A, et al.  Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini-review of the literature. <span><span class="ref-journal">Hepatol Commun. </span>2017;<span class="ref-vol">2</span>:142–7.</span> [<a href="/pmc/articles/PMC5796329/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5796329</span></a>] [<a href="/pubmed/29404521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29404521</span></a>]</div></dd></dl></div><div id="Pirfenidone.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Pirfenidone_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 24 June 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Pirfenidone.REF.kaplowitz.2013">Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013.<div><i>(Multi-authored textbook of hepatotoxicity published in 2013; does not discuss pirfenidone).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.angulo.2002.157">Angulo P, MacCarty RL, Sylvestre PB, Jorgensen RA, Wiesner RH, LaRusso NA, Lindor KD. Pirfenidone in the treatment of primary sclerosing cholangitis. <span><span class="ref-journal">Dig Dis Sci. </span>2002;<span class="ref-vol">47</span>:157–61.</span> [<a href="/pubmed/11837718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11837718</span></a>]<div><i>(Among 24 patients with primary sclerosing cholangitis treated with pirfenidone [2400 mg daily] for 1 year, AST and Alk P levels, histology and cholangiography findings did not change significantly, while adverse events were frequent and 1 patient had worsening of liver disease after 6 months of therapy leading to referral for liver transplantation).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.gahl.2002.234">Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, et al.  Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. <span><span class="ref-journal">Mol Genet Metab. </span>2002;<span class="ref-vol">76</span>:234–42.</span> [<a href="/pubmed/12126938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12126938</span></a>]<div><i>(Among 21 adults with Hermansky-Pudlak syndrome and progressive pulmonary fibrosis treated with pirfenidone or placebo for up to 3 years, serum ALT levels did not change and there were no serious hepatic adverse events).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.azuma.2005.1040">Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. <span><span class="ref-journal">Am J Respir Crit Care Med. </span>2005;<span class="ref-vol">171</span>:1040–7.</span> [<a href="/pubmed/15665326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15665326</span></a>]<div><i>(Among 107 patients with idiopathic pulmonary fibrosis treated with pirfenidone or placebo for 6 months, one patient discontinued therapy because of abnormal liver tests and one developed a liver cancer, both of whom were on pirfenidone).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.armend_rizborunda.2006.1663">Armend&#x000e1;riz-Borunda J, Islas-Carbajal MC, Meza-Garc&#x000ed;a E, Rinc&#x000f3;n AR, Lucano S, Sandoval AS, Salazar A, et al.  A pilot study in patients with established advanced liver fibrosis using pirfenidone. <span><span class="ref-journal">Gut. </span>2006;<span class="ref-vol">55</span>:1663–5.</span> [<a href="/pmc/articles/PMC1860119/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1860119</span></a>] [<a href="/pubmed/17047115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17047115</span></a>]<div><i>(Among 15 patients with chronic hepatitis C treated with pirfenidone for 12 months [1200 mg daily], ALT levels declined and paired liver biopsies showed improvements in fibrosis scores in 5 and stable scores in 10 patients).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.rockey.2008.939">Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. <span><span class="ref-journal">Clin Liver Dis. </span>2008;<span class="ref-vol">12</span>:939–62.</span> [<a href="/pmc/articles/PMC2610449/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2610449</span></a>] [<a href="/pubmed/18984475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18984475</span></a>]<div><i>(Review of the pathogenesis and cellular pathways of fibrosis in patients with chronic liver disease, and the status of antifibrotic agents, none of which have been shown to be effective in treating or preventing hepatic fibrosis).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.taniguchi.2010.821">Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, et al. Pirfenidone Clinical Study Group in Japan.  Pirfenidone in idiopathic pulmonary fibrosis. <span><span class="ref-journal">Eur Respir J. </span>2010;<span class="ref-vol">35</span>:821–9.</span> [<a href="/pubmed/19996196" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19996196</span></a>]<div><i>(Among 275 patients with idiopathic pulmonary fibrosis treated with pirfenidone [1200 or 1800 mg daily] or placebo for 12 months, the decline in lung vital capacity was less with pirfenidone [-0.08 and -0.09] than placebo [-0.16]; photosensitivity occurred in 51-52% on pirfenidone and GGT elevations in 22-23%; no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.obrien.2011.128">O'Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, Cardona H, Yao J, et al.  Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. <span><span class="ref-journal">Mol Genet Metab. </span>2011;<span class="ref-vol">103</span>:128–34.</span> [<a href="/pmc/articles/PMC3656407/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3656407</span></a>] [<a href="/pubmed/21420888" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21420888</span></a>]<div><i>(Among 35 patients with Hermansky-Pudlak syndrome and pulmonary fibrosis who were treated with pirfenidone [n=23] or placebo [n-12] for 1-3 years, mean serum ALT levels did not change and "there was no evidence of ... hepatic toxicity").</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.noble.2011.1760">Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, et al. CAPACITY Study Group.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">377</span>(9779):1760–9.</span> [<a href="/pubmed/21571362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21571362</span></a>]<div><i>(Among 779 patients with pulmonary fibrosis treated in two studies with pirfenidone [1197 or 2403 mg daily] or placebo, side effects included nausea [36%], dyspepsia [19%], anorexia [11%], photosensitivity [12%], rash [32%] and ALT elevations above 3 times ULN [4% vs &#x0003c;1% in controls]).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF11">Two new drugs for idiopathic pulmonary fibrosis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2014;<span class="ref-vol">56</span>(1457):123–4.</span> [<a href="/pubmed/25461229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25461229</span></a>]<div><i>(Concise review of the mechanism of action, efficacy and safety of pirfenidone and nintedanib for idiopathic pulmonary fibrosis mentions that both agents can increase hepatic enzyme levels and dose adjustment may be required).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.king.2014.2083">King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, et al. ASCEND Study Group.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">370</span>:2083–92.</span> [<a href="/pubmed/24836312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24836312</span></a>]<div><i>(Among 555 patients with idiopathic pulmonary fibrosis treated with pirfenidone [2403 mg/day] or placebo for 52 weeks, pirfenidone led to a lower rate of disease progression, but a higher rate of adverse events including ALT elevations above 3 times ULN in 2.9% [vs 0.7% in placebo controls], but all elevations "were reversible and without clinically significant consequences").</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.valeyre.2014.740">Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, et al.  Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. <span><span class="ref-journal">Respirology. </span>2014;<span class="ref-vol">19</span>:740–7.</span> [<a href="/pmc/articles/PMC4230393/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4230393</span></a>] [<a href="/pubmed/24836849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24836849</span></a>]<div><i>(Among 789 patients with idiopathic pulmonary fibrosis being monitored for safety for an average of 2.6 years, elevated ALT or AST values [above 3 times ULN] occurred in 2.7% on pirfenidone, but none developed clinically apparent liver injury, although 1% required drug discontinuation for the enzyme elevations).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.cottin.2015.58">Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. <span><span class="ref-journal">Eur Respir Rev. </span>2015;<span class="ref-vol">24</span>(135):58–64.</span> Erratum in Eur Respir Rev 2015; 24(137): 545. [<a href="/pubmed/25726556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25726556</span></a>]<div><i>(Analysis of long term, postmarketing monitoring of pirfenidone therapy of idiopathic pulmonary fibrosis focused on the frequency of common adverse events, including nausea [32%], diarrhea [19%], photosensitivity [9%] and rash [26%]).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to pirfenidone or other agents for pulmonary fibrosis).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.khanna.2016.1672">Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, Chen D, et al.  An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. <span><span class="ref-journal">J Rheumatol. </span>2016;<span class="ref-vol">43</span>(9):1672–9.</span> [<a href="/pubmed/27370878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27370878</span></a>]<div><i>(Among 63 patients with scleroderma and interstitial lung disease treated with pirfenidone in two dose escalation regimens for a total of 16 weeks, adverse events were common [96.8%] and mostly nausea, headache and fatigue; &#x0201c;minor elevations in liver function tests were sporadic and not considered clinically relevant&#x0201d; and ALT levels remained below 3 times ULN).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.lancaster.2017.317">Lancaster L, Morrison L, Auais A, Ding B, Iqbal A, Polman B, Flaherty KR. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: experience from 92 sites in an open-label US expanded access program. <span><span class="ref-journal">Pulm Ther. </span>2017;<span class="ref-vol">3</span>:317–25.</span> [<a href="/pmc/articles/PMC6964201/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6964201</span></a>] [<a href="/pubmed/32026347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32026347</span></a>]<div><i>(Among 1620 patients with idiopathic pulmonary fibrosis treated with pirfenidone in an expanded access program for an average of 23 weeks, adverse events occurred in 65%, which were severe in 3% and life-threatening in 0.2%, the most common adverse events being nausea [23%] and fatigue [20%] with ALT elevations above 5 times ULN in 13 patients [0.8%] usually by week 8, and hepatic enzyme elevations being considered severe in 10 [0.6%]).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.verma.2017.142">Verma N, Kumar P, Mitra S, Taneja S, Dhooria S, Das A, Duseja A, et al.  Drug idiosyncrasy due to pirfenidone presenting as acute liver failure: Case report and mini-review of the literature. <span><span class="ref-journal">Hepatol Commun. </span>2017;<span class="ref-vol">2</span>:142–7.</span> [<a href="/pmc/articles/PMC5796329/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5796329</span></a>] [<a href="/pubmed/29404521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29404521</span></a>]<div><i>(77 year old man with Parkinson disease and idiopathic pulmonary fibrosis developed jaundice 3-4 weeks after starting pirfenidone [bilirubin 12.8 mg/dL, ALT 526 U/L, Alk P 434 U/L, INR 2.1], with lactic acidosis and hepatic encephalopathy and progressive multiorgan failure dying 4 days after hospital admission: Case 1).</i></div></div></li><li><div class="bk_ref" id="Pirfenidone.REF.benesic.2019.1869">Benesic A, Jalal K, Gerbes AL. Acute liver failure during pirfenidone treatment triggered by co-medication with esomeprazole. <span><span class="ref-journal">Hepatology. </span>2019;<span class="ref-vol">70</span>:1869–71.</span> [<a href="/pubmed/31034631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31034631</span></a>]<div><i>(75 year old man with idiopathic pulmonary fibrosis developed liver test abnormalities a year after starting pirfenidone and 3 days after starting omeprazole for gastroesophageal reflux [bilirubin 6.4 mg/dL, ALT 973U/L, Alk P 379 U/L, INR 1.24], with progressive worsening despite stopping both drugs [bilirubin rising to 23.6 mg/dL], leading to hepatic and multiorgan failure and death 24 days after presentation).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548769</span><span class="label">PMID: <a href="/pubmed/31644078" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644078</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/PiperacillinTazob/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Piroxicam/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548769&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548769/?report=reader">PubReader</a></li><li><a href="/books/NBK548769/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548769" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548769" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Pirfenidone. [Updated 2020 Jun 24].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548769/pdf/Bookshelf_NBK548769.pdf">PDF version of this page</a> (103K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Pirfenidone+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Pirfenidone: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Pirfenidone" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Pirfenidone: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4864800" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4864800" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4864800" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643465" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nintedanib</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nintedanib<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21571362" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.</a><span class="source">[Lancet. 2011]</span><div class="brieflinkpop offscreen_noflow">Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Lancet. 2011 May 21; 377(9779):1760-9. Epub 2011 May 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27876247" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.</a><span class="source">[Lancet Respir Med. 2017]</span><div class="brieflinkpop offscreen_noflow">Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Lancet Respir Med. 2017 Jan; 5(1):33-41. Epub 2016 Nov 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24836312" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.</a><span class="source">[N Engl J Med. 2014]</span><div class="brieflinkpop offscreen_noflow">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">N Engl J Med. 2014 May 29; 370(22):2083-92. Epub 2014 May 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23404802" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.</a><span class="source">[Ann Pharmacother. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Potts J, Yogaratnam D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Pharmacother. 2013 Mar; 47(3):361-7. Epub 2013 Feb 12.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644078" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644078" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:55:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal103&amp;ncbi_phid=CE8AEAB4046729C100000000061701D9&amp;ncbi_session=CE8AEAB40468F2D1_1559SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548769%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548769&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548769/&amp;ncbi_pagename=Pirfenidone - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AEAB40468F2D1_1559SID /projects/books/PBooks@9.2 portal103 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>